
    
      First-in-Human (FIH), randomized, dose-escalation, double-blind, placebo-controlled single
      dose in healthy volunteers.

      The single rising dose study will enroll 8 subjects per cohort (6 verum, 2 placebo), up to a
      maximum tolerated dose, defined by stopping rules. 6 dose levels are anticipated. Study drug
      will be administered as i.v. infusion on Day 1. The decision to escalate the dose by the dose
      escalation committee (DEC) will be based on an interim analysis of clinical safety and safety
      laboratory data.
    
  